Form 4: Rocket Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- Kinnari Patel, an executive at Rocket Pharmaceuticals, sold 767 shares of common stock on May 20, 2025, at a price of $6.446 per share.
- The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Patel directly owns 441,927 shares of Rocket Pharmaceuticals common stock.
- Patel also indirectly owns 26,774 shares through her spouse and 104,927 shares through Adaptive Technology LLC, a limited liability company owned and managed by her husband.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be related to tax obligations, a common occurrence when RSUs vest.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of stock sale transaction. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Rocket Pharmaceuticals, Kinnari Patel, stock sale, Form 4, insider trading, RSUs, tax obligations, Adaptive Technology LLC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.